Request Demo
Recent blog posts
Latest Hotspot
8 min read
Efsubaglutide Alfa Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Efsubaglutide Alfa: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07659886 Vancomycin Hydrochloride Fractures, Open Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07659886, evaluating Vancomycin Hydrochloride in Fractures, Open: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07660094 Pembrolizumab metastatic non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07660094, evaluating Pembrolizumab in metastatic non-small cell lung cancer: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Ebronucimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Ebronucimab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07658872 Sintilimab Locally Advanced Gastroesophageal Junction Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07658872, evaluating Sintilimab in Locally Advanced Gastroesophageal Junction Adenocarcinoma: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Avutometinib/Defactinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Avutometinib/Defactinib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07660198 Multivalent Pneumococcal Conjugate Vaccine(Pfizer) Pneumococcal Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07660198, evaluating Multivalent Pneumococcal Conjugate Vaccine(Pfizer) in Pneumococcal Infections: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Prusogliptin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Prusogliptin: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07661940 SP16-3M Acute Kidney Injury Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07661940, evaluating SP16-3M in Acute Kidney Injury: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2011260019 Izalontamab Brengitecan Squamous non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into JPRN-jRCT2011260019, evaluating Izalontamab Brengitecan in Squamous non-small cell lung cancer: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Fotagliptin Benzoate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Fotagliptin Benzoate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
JPRN-jRCTs031260239 [18F]FAPI-74 Idiopathic Inflammatory Myopathies Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into JPRN-jRCTs031260239, evaluating [18F]FAPI-74 in Idiopathic Inflammatory Myopathies: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.